PBAC's latest decision on Leuprorelin: Recommended (2024). Considered for Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate, and central precocious puberty.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
5
first 2014
Submissions
5
2014 → 2024
Eligible population
Adults with locally advanced (stage C) or metastatic (stage D) prostate carcinoma, and children with central precocious puberty (females prior to 10th birthday with onset prior to 8th birthday; males prior to 11th birthday with onset prior to 9th birthday).
Therapy area
Endocrinology
Line of therapy
Not applicable
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Eligard with current injection device
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated as drugs are equi-effective at same cost.
Submission history
Nov 2014: Recommended with restriction · Authority Required
Jul 2015: Recommended with restriction · Authority Required
Mar 2016: Recommended with restriction · Restricted
Jul 2019: Recommended with restriction · Restricted